kadsurenone

platelet-activating factor receptor antagonist from Chinese herbal plant, haifenteng; structure given in first source; RN given refers to (2s-(2alpha,3beta,3aalpha))-isomer

Also Known As:

Networked: 8 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hou, Tianhui: 1 article (08/2018)
2.	Ji, Yingzheng: 1 article (08/2018)
3.	Li, Shichang: 1 article (08/2018)
4.	Li, Zhenxi: 1 article (08/2018)
5.	Lou, Yan: 1 article (08/2018)
6.	Qian, Ming: 1 article (08/2018)
7.	Tang, Liang: 1 article (08/2018)
8.	Wang, Dongsheng: 1 article (08/2018)
9.	Wei, Haifeng: 1 article (08/2018)
10.	Wu, Zhipeng: 1 article (08/2018)

Related Diseases

1.	Shock 01/01/1986 - "Ovalbumin challenge in sensitized guinea pigs in vivo resulted in airway constriction, circulatory failure and an abrupt fall in continuously measured platelet count by 75 +/- 12%, followed by death of all animals within 5-8 min. Pretreatment with diphenhydramine, BW-755C and kadsurenone (or alprazolam) improved survival to 64% (i.e., 7 of 11 animals) compared to a survival rate of 0% (i.e., 0 of 8 vehicle treated controls). "
2.	Neoplasm Metastasis (Metastasis) 08/01/2018 - "Therefore, targeting PAF/PTAFR by Kadsurenone may be a promising treatment strategy for BC bone metastases." 08/01/2018 - "Kadsurenone is a useful and promising treatment strategy for breast cancer bone metastases by blocking the PAF/PTAFR signaling pathway."
3.	Breast Neoplasms (Breast Cancer) 08/01/2018 - "Kadsurenone is a useful and promising treatment strategy for breast cancer bone metastases by blocking the PAF/PTAFR signaling pathway."
4.	Edema (Dropsy) 01/14/1986 - "Indomethacin did not inhibit the peak edematous response whereas both PAF antagonists, kadsurenone and L-652,731, inhibit the PAF-induced rat foot edema (PFE). " 06/01/1989 - "The PAF antagonists, CV-6202 (iv) and kadsurenone (coinjected) reduced the PLA2-induced edema, whereas high doses of the corticosteroids, dexamethasone and hydrocortisone, were also effective. " 06/01/1989 - "Coinjection of phenidone (lipoxygenase inhibitor, 50 micrograms), indomethacin (cyclooxygenase inhibitor, 50 micrograms), cyproheptadine (antihistamine/antiserotonin, 50 micrograms), aristolochic acid (putative PLA2 inhibitor, 100 micrograms), or kadsurenone (PAF antagonist, 50 micrograms) with PLA2 (1 microgram/paw) resulted in partial reduction (44.5, 34.2, 54.7, 64, and 50% inhibition, respectively) of edema formation. "
5.	Ischemia 12/14/1987 - "Kadsurenone (3 mg/kg) administered 5 min prior to ischemia and continuously (1 mg/kg/hr) throughout ischemia and recovery significantly enhanced recovery of cortical somatosensory evoked response (CSER) amplitude (% of baseline) when compared to controls (27-36% vs 9-14%, p less than 0.05). " 12/14/1987 - "We treated four anesthetized dogs (Canis familiaris) with the platelet activating factor (PAF) receptor antagonist kadsurenone prior to 60 min of multifocal ischemia induced by air embolism, and measured neuronal recovery, blood flow and autologous 111In-labeled platelet accumulation for 4 h after ischemia. "

Related Drugs and Biologics

1.	4,5- Dihydro- 1- (3- (trifluoromethyl)phenyl)- 1H- pyrazol- 3- amine
2.	Ovalbumin
3.	Diphenhydramine (Benadryl)
4.	Alprazolam (Xanax)
5.	Indomethacin (Indometacin)
6.	Cyclooxygenase Inhibitors
7.	Lipoxygenase Inhibitors
8.	Platelet Activating Factor
9.	Hydrocortisone (Cortisol)
10.	Histamine Antagonists (Antihistamines)

Related Therapies and Procedures

1.	Controlled Hypotension